EPO Board of Appeal OKs Agennix Patent Claims

Law360, New York (March 9, 2004, 12:00 AM EST) -- The European Patent Office's Technical Board of Appeal has decided in favor of Agennix in litigation over its European patent covering the cDNA sequence and expression of recombinant human lactoferrin (rhLF), the company said Tuesday.

All of Agennix's patent claims were upheld as valid and enforceable by the board of appeal, the highest and final authority on European patents, the company said.

Agennix's patent had been opposed by rival Pharming Group NV of the Netherlands.

European patent number 0471011, which covers the cDNA sequence for human...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.